Physician profile
Jiwon Yoo
NPI 1942700729
$8,033.19
in general payments reported to CMS, 2019-2025
41 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,019 · 2022: $1,576 · 2023: $1,426 · 2024: $1,685 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,393 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.20 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,706.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,103.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $893.97 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $680.22 | 2021-2023 | |
| Lilly USA, LLC | $610.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $314.58 | 2022-2024 | |
| Glaxosmithkline, LLC. | $246.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $194.11 | 2021-2025 | Otezla, Repatha, Repatha |
| Esperion Therapeutics, INC. | $145.48 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $141.08 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $139.60 | 2022 | |
| Merck Sharp & Dohme LLC | $130.31 | 2021-2025 | Lagevrio, Verquvo, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $126.94 | 2021 | |
| Exact Sciences Corporation | $125.70 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $124.32 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiwon Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.